GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Repare Therapeutics Inc (NAS:RPTX) » Definitions » Cash Flow for Dividends

RPTX (Repare Therapeutics) Cash Flow for Dividends : $0.00 Mil (TTM As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Repare Therapeutics Cash Flow for Dividends?

Repare Therapeutics's cash flow for dividends for the three months ended in Sep. 2024 was $0.00 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.


Repare Therapeutics Cash Flow for Dividends Historical Data

The historical data trend for Repare Therapeutics's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Repare Therapeutics Cash Flow for Dividends Chart

Repare Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow for Dividends
Get a 7-Day Free Trial - - - - -

Repare Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Repare Therapeutics Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Repare Therapeutics Cash Flow for Dividends Related Terms

Thank you for viewing the detailed overview of Repare Therapeutics's Cash Flow for Dividends provided by GuruFocus.com. Please click on the following links to see related term pages.


Repare Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
7210 Frederick-Banting Street, Suite 100, Saint-Laurent, QC, CAN, H4S 2A1
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company derives maximum revenue from Canada.
Executives
Maria Koehler officer: EVP, Chief Medical Officer C/O REPARE THERAPEUTICS INC., 7210 FREDERICK-BANTING, SUITE 100, ST-LAURENT A8 H4S 2A1
Michael Zinda officer: EVP, Chief Science Officer C/O REPARE THERAPEUTICS INC., 7210 FREDERICK-BANTING, SUITE 100, ST-LAURENT A8 H4S 2A1
Steve Forte officer: EVP, Chief Financial Officer C/O REPARE THERAPEUTICS INC., 7210 FREDERICK-BANTING, SUITE 100, ST-LAURENT A8 H4S 2A1
Lloyd Mitchell Segal officer: President and CEO 2150 ST. ELZEAR BLVD. WEST, LAVAL A8 H7L 4A8
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Susan Molineaux director C/O CALITHERA BIOSCIENCES, INC., 343 OYSTER POINT BLVD., SUITE 200, SOUTH SAN FRANCISCO CA 94080
Davis Jerel director, 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Vantage I, L.p. 10 percent owner ONE SANSOME, SUITE 1650, SAN FRANCISCO CA 94104
Versant Ventures V, Llc 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Thomas Civik director C/O FOUNDATION MEDICINE, INC., 150 SECOND STREET, CAMBRIDGE MA 02141
Bvf Ii Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Partners Os Ltd. other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Bvf Partners L P/il 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104